ALEXANDRIA, Va., Sept. 30, 2013 /PRNewswire/ -- Food and Drug Administration (FDA) announced the requirement of a Boxed Warning for the anti-cancer immunosuppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab). The Boxed Warning is specific to the risk of reactivating......
More...







